ST. PAUL, Minn., Feb. 21, 2017 /PRNewswire/ -- EnteroMedics
Inc. (NASDAQ:ETRM), the developer of medical devices using
neuroblocking technology to treat obesity, metabolic diseases and
other gastrointestinal disorders, today announced that on
February 17, 2017, Nasdaq issued a
determination that the company has evidenced compliance with all
requirements for continued listing on The Nasdaq Capital Market
and, accordingly, the listing qualifications matter has been
closed.
The Company also announced that it will host a conference call
on Tuesday, March 7, 2017 at
11:00 AM Eastern Time to discuss
financial results for the fourth quarter ended December 31, 2016 and to provide an update on the
commercialization of the Company's vBloc® Neurometabolic
Therapy.
Conference Call Details
The conference call may be accessed by dialing (877) 280-7473
(U.S. and Canada) or (707)
287-9370 (international), and entering passcode 75853218. A replay
of the call will be available from March 7,
2017 at 2:00 PM Eastern Time
through March 14, 2017 at
3:00 PM Eastern Time by dialing (855)
859-2056 (U.S. and Canada) or
(404) 537-3406 (international) and entering passcode 75853218.
To access the live webcast, visit the events page of the
investor relations section of EnteroMedics' website at
www.enteromedics.com. A replay of the webcast will be available
immediately after the conference call.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of its neuroscience based
technology to treat obesity and metabolic diseases.
vBloc® Neurometabolic Therapy, delivered by a
pacemaker-like device called the vBloc® System, is
designed to intermittently block the vagus nerves using
high-frequency, low-energy, electrical
impulses. EnteroMedics' vBloc® System has
received U.S. Food and Drug Administration approval and
CE Mark.
Information about the vBloc® System and
vBloc® Neurometabolic Therapy
You should not have an implanted vBloc® System
if you have cirrhosis of the liver, high blood pressure in the
veins of the liver, enlarged veins in your esophagus or a
significant hiatal hernia of the stomach; if you need magnetic
resonance imaging (MRI); if you have a permanently implanted,
electrical medical device; or if you need a diathermy procedure
using heat. The most common related adverse events that were
experienced during clinical study of the vBloc System included
pain, heartburn, nausea, difficulty swallowing, belching, wound
redness or irritation, and constipation.
Talk with your doctor about the full risks and benefits of vBloc
Therapy and vBloc System. For additional prescribing information,
please visit www.enteromedics.com.
If you are interested in learning more about vBloc
Neurometabolic Therapy, please visit www.vbloc.com or
call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements
about EnteroMedics Inc. Our actual results could differ
materially from those discussed due to known and unknown risks,
uncertainties and other factors including our limited history of
operations; our losses since inception and for the foreseeable
future; our limited commercial sales experience with our
vBloc® System for the treatment of obesity in the
United States or in any foreign market other
than Australia and the European Community; our ability to
maintain compliance with the Nasdaq continued listing requirements;
our ability to commercialize our vBloc® System; our
dependence on third parties to initiate and perform our clinical
trials; the need to obtain regulatory approval for any
modifications to our vBloc® System; physician adoption
of our vBloc® System and vBloc®
Neurometabolic Therapy; our ability to obtain third party coding,
coverage or payment levels; ongoing regulatory compliance; our
dependence on third party manufacturers and suppliers; the
successful development of our sales and marketing capabilities; our
ability to raise additional capital when needed; international
commercialization and operation; our ability to attract and retain
management and other personnel and to manage our growth
effectively; potential product liability claims; potential
healthcare fraud and abuse claims; healthcare legislative reform;
and our ability to obtain and maintain intellectual property
protection for our technology and products. These and additional
risks and uncertainties are described more fully in the Company's
filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the
annual report on Form 10-K filed March 28, 2016. We are
providing this information as of the date of this press release and
do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-regains-compliance-with-nasdaq-listing-requirement-300410372.html
SOURCE EnteroMedics Inc.
